Cornell professor says there is evidence weight impacts employment as NYC puts new discrimination law into effect
Cornell University
In a pioneering breakthrough within the realm of literature, scientists have harnessed the power of purified beta-glucanase to transform broiler wheat diets.
The world’s total population is expected to reach 9.9 billion by 2050. This rapid increase in population is boosting the demand for agriculture to cater for the increased demand. Below are some of the latest research and features on agriculture and farming in the Agriculture channel on Newswise.
By: Bill Wellock | Published: November 14, 2023 | 2:43 pm | SHARE: The U.S. Food and Drug Administration recently approved the medication Zepbound for weight management treatment.Tirzepatide, the active ingredient in the Eli Lilly and Company’s trademarked Zepbound, was already approved to help improve blood sugar (glucose) in adults with type 2 diabetes mellitus.
In what is believed to be the largest study of the association between BMI and postoperative complications following chest masculinization surgery, researchers at the Johns Hopkins Center for Transgender and Gender Expansive Health provide evidence that BMI is a poor metric for determining who should be approved for the gender transitioning procedure.
New study shows that most people taking semaglutide do not develop diabetic retinopathy or experience a worsening of existing diabetic retinopathy.
A new large-scale study led by researchers at the University of Cincinnati and Northwell Health, New York's largest health care provider, found the drug metformin can help prevent or reduce weight gain in youth taking medication to treat bipolar disorder.
More weight lost among people who fasted, compared to calorie restriction
Patients with previous bariatric surgery who undergo body contouring (BC) regain more weight at long-term follow-up, compared to BC patients who did not have bariatric surgery, reports a study in the November issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
In a first-of-its-kind study, researchers from the University of California, Irvine have discovered an extraordinary surge in the utilization of weight loss-associated GLP-1 receptor agonists, a class of medications commonly used in the treatment of Type 2 diabetes and obesity, that is poised to accelerate, based on emerging clinical evidence.
Scientists from Immanuel Kant Baltic Federal University on the base of literary sources have described in detail the connection between intracellular processes in mitochondria and metabolic disorders in human’s organism that lead to obesity and cardiovascular diseases.
The Integrated Program is dedicated to helping people lose weight and keep it off in the most healthy and appropriate way.
Improving insulin resistance with metformin, a medication used to treat Type 2 diabetes, reduced the chances of developing kidney disease in a prepubescent obese rat model, according to a new study from the University of Mississippi Medical Center.
Scientists have uncovered why night shift work is associated with changes in appetite in a new University of Bristol-led study. The findings, published in Communications Biology, could help the millions of people that work through the night and struggle with weight gain.
Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association’s flagship journal Circulation.
These drugs are not the be-all and end-all to weight-loss therapy, wrote Dr. Michael Schwartz in a commentary published Oct. 2 in The Journal of Clinical Investigation. His co-author was Sophie Yang Gou, a postdoctoral fellow in Schwartz’s lab at the University of Washington School of Medicine. Many experts seem to be saying “OK, we’ve fixed this problem. We’re done,” noted Schwartz, who co-directs the UW Medicine Diabetes Institute. That is simply not the case, he said.
Researchers at University of Galway have taken a significant step forward in the management of gestational diabetes mellitus after a clinical trial involving pregnant women provided new hope for expectant mothers suffering the condition.